Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) Following Appreciation
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Halozyme Therapeutics Inc. (HALO)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 3,290,665 | $241,337,371 | +30% | 0.15% |
| 2. | D E Shaw D. E. Shaw | 2,650,375 | $194,378,503 | +161% | 0.11% |
| 3. | 111,500,000 | $127,976,355 | +72% | 7.68% | |
| 4. | 88,500,000 | $124,702,193 | +72% | 0.05% | |
| 5. | Millennium Management Israel Englander | 1,227,584 | $90,031,011 | +78% | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.24 | 17,543 | $249,780.74 | 277,553 | 2020-03-19 | Filing | |
| $14.25 | 17,543 | $249,982.49 | 260,010 | 2020-03-19 | Filing | |
| $14.19 | 17,543 | $248,933.42 | 242,467 | 2020-03-19 | Filing | |
| $17.24 | 10,000 | $172,384.00 | 10,000 | 2015-08-20 | Filing | |
| $17.24 | 10,000 | $172,384.00 | 10,000 | 2015-08-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $71.60 | 829 | $59,356.40 | 42,123 | 2025-12-01 | Filing | |
| $71.60 | 261 | $18,687.60 | 708,719 | 2025-12-01 | Filing | |
| $70.36 | 500 | $35,181.00 | 708,980 | 2025-12-01 | Filing | |
| $69.44 | 5,402 | $375,120.28 | 709,480 | 2025-12-01 | Filing | |
| $68.51 | 10,406 | $712,935.87 | 714,882 | 2025-12-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 12,860,199 | $943,166,956 | 0.02% | |
| 2. | 11,629,786 | $852,928,505 | 0.01% | |
| 3. | 5,019,207 | $368,108,641 | 0.01% | |
| 4. | 3,245,770 | $238,044,774 | 0.04% | |
| 5. | 2,945,751 | $216,041,378 | 0.03% |
News See All
This Biotech Stock Is Up 50% in 2025, But Redditors Say It Has More Upside - Here's Why
We recently published 10 Best Small-Cap Stocks With Huge Potential According to Reddit as Market Looks Beyond AI Trade. Halozyme Therapeutics, Inc.
10 Best Small-Cap Stocks With Huge Potential According to Reddit as Market Looks Beyond AI Trade
Investors remain skeptical about the AI trade amid valuation and demand concerns after major tech stocks enjoyed strong gains over the past few months.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2025 Earnings Call Transcript
Operator: Good afternoon. My name is Tiffany, and I will be your conference operator today.
H.C. Wainwright Maintains a Buy on Halozyme Therapeutics (HALO), Keeps the PT at $90
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Mitchell Kapoor maintained a Buy rating on Halozyme Therapeutics, Inc.
9 Most Profitable Biotech Stocks to Buy
On October 6, StemPoint Capital CIO Michelle Ross appeared on CNBC’s ‘Closing Bell’ to talk about the biotech space.
Benchmark Sees More Upside for Halozyme Therapeutics (HALO), Hikes Price Target
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the best biotech stocks to buy. On September 24, Benchmark maintained its Buy rating on Halozyme Therapeutics, Inc.
14 Best Biotech Stocks to Buy Right Now
The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector of late.
Where is Halozyme Therapeutics (HALO) Headed According to Analysts?
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best affordable biotech stocks to invest in now. On August 18, Morgan Stanley raised the firm’s price target on Halozyme Therapeutics, Inc.
12 Affordable Biotech Stocks to Invest In Now
On September 4, Mizuho healthcare strategist Jared Holz appeared on CNBC's ‘Power Lunch’ to talk about the changing sentiment in the healthcare sector, the differences in the biotech ETFs, and more...
Hedge Fund Resource Center Billionaire Hedge Funds
